Australia markets close in 6 hours 3 minutes

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
502.60+7.96 (+1.61%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 553.84B
Enterprise value 351.46B
Trailing P/E 16.47
Forward P/E 112.45
PEG ratio (5-yr expected) 10.94
Price/sales (ttm)6.48
Price/book (mrq)4.74
Enterprise value/revenue 36.19
Enterprise value/EBITDA 714.58

Trading information

Stock price history

Beta (5Y monthly) 0.19
52-week change 3-11.51%
S&P500 52-week change 348.25%
52-week high 3664.64
52-week low 3441.00
50-day moving average 3473.77
200-day moving average 3511.72

Share statistics

Avg vol (3-month) 31.01M
Avg vol (10-day) 3890.09k
Shares outstanding 5104.86M
Implied shares outstanding 6106.71M
Float 99.29M
% held by insiders 13.00%
% held by institutions 187.84%
Shares short (30 Mar 2021) 42.21M
Short ratio (30 Mar 2021) 42.36
Short % of float (30 Mar 2021) 42.85%
Short % of shares outstanding (30 Mar 2021) 42.06%
Shares short (prior month 25 Feb 2021) 42.32M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)30 Dec 2020

Profitability

Profit margin 42.28%
Operating margin (ttm)39.65%

Management effectiveness

Return on assets (ttm)12.88%
Return on equity (ttm)31.77%

Income statement

Revenue (ttm)8.31B
Revenue per share (ttm)77.23
Quarterly revenue growth (yoy)20.00%
Gross profit (ttm)4.46B
EBITDA 3.53B
Net income avi to common (ttm)3.51B
Diluted EPS (ttm)30.52
Quarterly earnings growth (yoy)45.10%

Balance sheet

Total cash (mrq)3.59B
Total cash per share (mrq)34.44
Total debt (mrq)2.71B
Total debt/equity (mrq)24.56
Current ratio (mrq)3.62
Book value per share (mrq)106.05

Cash flow statement

Operating cash flow (ttm)2.62B
Levered free cash flow (ttm)948.45M